{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T08:21:18Z","timestamp":1777105278514,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ejca.2021.12.028","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T12:44:23Z","timestamp":1642769063000},"page":"152-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Cetuximab and vemurafenib plus FOLFIRI\u00a0(5-fluorouracil\/leucovorin\/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial"],"prefix":"10.1016","volume":"163","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2542-7361","authenticated-orcid":false,"given":"Zhan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1000-2942","authenticated-orcid":false,"given":"Bao-Dong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Yang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao-Miao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-Yan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Ping","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Xing","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Dong","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing-Nan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Sheng","family":"Zang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6892","key":"10.1016\/j.ejca.2021.12.028_bib1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"7417","key":"10.1016\/j.ejca.2021.12.028_bib2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature11404","article-title":"Comprehensive genomic characterization of squamous cell lung cancers","volume":"489","author":"Cancer Genome Atlas Research","year":"2012","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.ejca.2021.12.028_bib3","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: powering precision medicine through an international consortium","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.ejca.2021.12.028_bib4","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","article-title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis","volume":"11","author":"De Roock","year":"2010","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2021.12.028_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131046","article-title":"High BRAF mutation frequency and marked survival differences in subgroups according to KRAS\/BRAF mutation status and tumor tissue availability in a prospective population-based metastatic colorectal cancer cohort","volume":"10","author":"Sorbye","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ejca.2021.12.028_bib6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup Analyses from the BEACON study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2021.12.028_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ccell.2017.12.004","article-title":"Clinical sequencing defines the genomic landscape of metastatic colorectal cancer","volume":"33","author":"Yaeger","year":"2018","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.ejca.2021.12.028_bib8","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.annonc.2021.03.206","article-title":"Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines","volume":"32","author":"Grothey","year":"2021","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2021.12.028_bib9","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"Cremolini","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2021.12.028_bib10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1056\/NEJMc0904160","article-title":"BRAF mutation in metastatic colorectal cancer","volume":"361","author":"Tol","year":"2009","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ejca.2021.12.028_bib11","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2021.12.028_bib12","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","article-title":"Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies","volume":"20","author":"Venderbosch","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"35","key":"10.1016\/j.ejca.2021.12.028_bib13","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1200\/JCO.2008.18.0786","article-title":"Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer","volume":"26","author":"Di Nicolantonio","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.12.028_bib14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(19)30862-9","volume":"21","author":"Cremolini","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.12.028_bib15","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.01225","article-title":"Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer","author":"Cremolini","year":"2020","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.ejca.2021.12.028_bib16","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","article-title":"Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer","volume":"33","author":"Kopetz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2021.12.028_bib17","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2021.12.028_bib18","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1158\/1078-0432.CCR-14-2779","article-title":"Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients","volume":"21","author":"Yaeger","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2021.12.028_bib19","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","article-title":"Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer","volume":"8","author":"Corcoran","year":"2018","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.ejca.2021.12.028_bib20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.20.01994","article-title":"Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)","volume":"39","author":"Kopetz","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2021.12.028_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Contr Clin Trials"},{"issue":"suppl 15","key":"10.1016\/j.ejca.2021.12.028_bib22","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1200\/JCO.2016.34.15_suppl.3544","article-title":"Phase 2 results: encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC)","volume":"34","author":"Tabernero","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2021.12.028_bib23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","article-title":"EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib","volume":"2","author":"Corcoran","year":"2012","journal-title":"Cancer Discov"},{"issue":"7387","key":"10.1016\/j.ejca.2021.12.028_bib24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"issue":"suppl 4","key":"10.1016\/j.ejca.2021.12.028_bib25","article-title":"ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600Eemutant metastatic colorectal cancer","volume":"30","author":"A","year":"2019","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2021.12.028_bib26","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ejca.2021.12.028_bib27","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921013095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921013095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:35:42Z","timestamp":1760733342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921013095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":27,"alternative-id":["S0959804921013095"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.12.028","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cetuximab and vemurafenib plus FOLFIRI\u00a0(5-fluorouracil\/leucovorin\/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.12.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}